ML

Michael Lee

Managing Director at Syngenta Group Ventures

Basel Metropolitan Area

Invests in

Stages:

Locations:

  • Min Investment:

    $100,000.00
  • Max Investment:

    $5,000,000.00
  • Target Investment:

    $1,500,000.00

Skills

Startups
R&D
Venture Capital
Corporate Venture Capital
Lifesciences
Investments
New Business Development
Emerging Markets
Business Development

Education

Work Experience

  • Syngenta Group Ventures, Managing Director

    2013

    Syngenta Group Ventures identifies early stage food and agriculture-related companies with a strong technology base or new business model. I look after the full range of investment activities outside the Americas.

  • Board Observer

    2021

    Sayurbox is bringing a more efficient middlestream to benefit farmers with faster payments and better market access at one end and a digitally-accessible product to consumers at the other.

  • Non Executive Director

    2015

    Phytech offers corn, cotton, and perennial fruit/nut growers increased yields with reduced water consumption. Used by some of the largest growers in the world.

2015 - 2023

  • Non Executive Director

    2015 - 2023

    Biognosys is the leading proteomics company offering innovative services and products for highly multiplexed protein quantification. Sold to Bruker.

BioPhero

2018 - 2022

  • Non Executive Director

    2018 - 2022

    BioPhero is a pioneer in providing low-cost bio-based pheromones for pest management. Its mission is to provide sustainable agriculture, via safe pheromone-based products. Sold to FMC.

2020 - 2022

  • Non Executive Director

    2020 - 2022

    WeedOUT is developing a biological species specific herbicide to help farmers manage resistant weeds.

2019 - 2021

  • Board Observer

    2019 - 2021

    Stable is a risk management platform that helps businesses around the world protect themselves from volatile commodity prices.

2007 - 2009

  • Board Observer

    2007 - 2009

    Arecor Therapeutics has developed protein and peptide stabilization technology, useful for extending the shelf life of biopharmaceuticals. IPO-ed on London AIM [AREC].

1996 - 2009

  • Various

    1996 - 2009

    Various roles in R&D and Corporate Venturing Group

2005 - 2007

  • Fellowship

    2005 - 2007